Comments
Loading...

Vertex Pharmaceuticals Analyst Ratings

VRTXNASDAQ
Logo brought to you by Benzinga Data
$504.77
1.850.37%
At close: -
$506.75
1.980.39%
After Hours: Mar 14, 7:49 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$586.00
Lowest Price Target1
$408.00
Consensus Price Target1
$507.84

Vertex Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VRTX | Benzinga

Vertex Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Vertex Pharmaceuticals Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
4
1
1
Nov 24
6
1
Dec 24
5
1
Jan
3
2
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.3
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

RBC Capital
Canaccord Genuity
Truist Securities
Scotiabank
Cantor Fitzgerald

1calculated from analyst ratings

Analyst Ratings for Vertex Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Vertex Pharmaceuticals (VRTX) stock?

A

The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by RBC Capital on February 20, 2025. The analyst firm set a price target for $408.00 expecting VRTX to fall to within 12 months (a possible -19.49% downside). 77 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Vertex Pharmaceuticals (VRTX)?

A

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by RBC Capital, and Vertex Pharmaceuticals maintained their sector perform rating.

Q

When was the last upgrade for Vertex Pharmaceuticals (VRTX)?

A

The last upgrade for Vertex Pharmaceuticals Inc happened on February 12, 2025 when Canaccord Genuity raised their price target to $424. Canaccord Genuity previously had a sell for Vertex Pharmaceuticals Inc.

Q

When was the last downgrade for Vertex Pharmaceuticals (VRTX)?

A

The last downgrade for Vertex Pharmaceuticals Inc happened on January 30, 2025 when Wells Fargo changed their price target from $460 to $460 for Vertex Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Vertex Pharmaceuticals (VRTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on February 20, 2025 so you should expect the next rating to be made available sometime around February 20, 2026.

Q

Is the Analyst Rating Vertex Pharmaceuticals (VRTX) correct?

A

While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a maintained with a price target of $407.00 to $408.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $506.75, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch